Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
Irene Konstantopoulou, PhD
Advertisement
Articles by Irene Konstantopoulou, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Durvalumab Plus BCG Earns FDA Approval For High-Risk NMIBC
2
FDA Approves Pivekimab Sunirine in Rare Hematologic Malignancy
3
ASCO 2026: The Presentations That May Shape The Future of Multiple Myeloma
4
This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test
5